We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+18.13%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$767M
AUM Growth
+$137M
Cap. Flow
+$31.2M
Cap. Flow %
4.08%
Top 10 Hldgs %
34.48%
Holding
123
New
27
Increased
33
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$14.4M
2
CYTK icon
Cytokinetics
CYTK
+$12.9M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.3M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$7.27M

Top Sells

Rank Stock Value
1
NVMI
Nova
NVMI
+$14.5M
2
TSEM icon
Tower Semiconductor
TSEM
+$8.98M
3
FOLD
Amicus Therapeutics
FOLD
+$8.72M
4
CLBT icon
Cellebrite
CLBT
+$8.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
2 Miscellaneous 10.43%
3 Technology 7.55%
4 Utilities 1.93%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
76
Alnylam Pharmaceuticals
ALNY
$35.4B
$3.25M 0.42%
+10,800
New +$3.26M
KURA icon
77
Kura Oncology
KURA
$1.17B
$3.24M 0.42%
295,039
-483
-0.2% -$4.56K
KOD icon
78
Kodiak Sciences
KOD
$2.29B
$3.19M 0.42%
81,796
-33,000
-29% -$1.28M
ORA icon
79
Ormat Technologies
ORA
$6.41B
$3.05M 0.4%
28,015
-40,235
-59% -$4.99M
CTNM
80
Contineum Therapeutics
CTNM
$661M
$3.01M 0.39%
183,475
+10,000
+6% +$131K
LRMR icon
81
Larimar Therapeutics
LRMR
$398M
$2.82M 0.37%
+926,004
New +$3.68M
IMMX icon
82
Immix Biopharma
IMMX
$985M
$2.78M 0.36%
+270,000
New +$2.5M
AMGN icon
83
Amgen
AMGN
$240B
$2.72M 0.35%
7,500
– –
ABVX
84
PUT
Abivax
ABVX
$9.95B
$2.67M 0.35%
+20,000
New +$2.26M
BHVN icon
85
Biohaven
BHVN
$2.4B
$2.45M 0.32%
164,437
-429,563
-72% -$4.62M
CEG icon
86
Constellation Energy
CEG
$101B
$2.45M 0.32%
+9,850
New +$2.77M
VSTM icon
87
Verastem
VSTM
$723M
$2.42M 0.32%
632,632
+288,954
+84% +$1.4M
TENX icon
88
CALL
Tenax Therapeutics
TENX
$66.6M
$1.86M 0.24%
+127,600
New +$1.63M
TENX icon
89
Tenax Therapeutics
TENX
$66.6M
$1.75M 0.23%
120,200
-15,815
-12% -$202K
TSHA icon
90
Taysha Gene Therapies
TSHA
$1.81B
$1.7M 0.22%
+250,000
New +$1.48M
GPCR icon
91
Structure Therapeutics
GPCR
$3.38B
$1.53M 0.2%
28,600
-22,200
-44% -$982K
UPB
92
Upstream Bio Inc
UPB
$333M
$1.52M 0.2%
219,700
-138,300
-39% -$1.16M
VYGR icon
93
Voyager Therapeutics
VYGR
$208M
$1.5M 0.2%
427,554
-42,207
-9% -$160K
ORGO icon
94
Organogenesis Holdings
ORGO
$211M
$1.34M 0.17%
550,000
– –
IKT icon
95
Inhibikase Therapeutics
IKT
$352M
$1.32M 0.17%
+649,309
New +$1.16M
ORIC icon
96
CALL
Oric Pharmaceuticals
ORIC
$1.32B
$1.08M 0.14%
+100,000
New +$907K
CRIS icon
97
Curis
CRIS
$3.32M
$1.03M 0.13%
4,950
-94,797
-95% -$972K
STTK icon
98
Shattuck Labs
STTK
$699M
$600K 0.08%
86,461
-194,325
-69% -$1.21M
TRAX
99
First Tracks Biotherapeutics
TRAX
$1.52B
$561K 0.07%
+27,876
New +$521K
SKYE icon
100
Skye Bioscience
SKYE
$7.88M
$471K 0.06%
84,866
– –
1 2 3
4
5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sphera Funds Management held 123 positions worth $767M, up 22% from $630M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management deployed $31.2M of net new capital in Q2 2026, opening 27 new positions and adding to 33 existing holdings. Its largest new stake was Insmed: 118,800 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Nova, an estimated $14.5M trimmed.

  • Sphera Funds Management's largest Q2 2026 buy was Insmed: 118,800 shares worth $12.7M.
  • Sphera Funds Management added most to Cytokinetics in Q2 2026, an estimated $12.9M increase.
  • Sphera Funds Management's biggest Q2 2026 reduction was Nova, cutting an estimated $14.5M.
  • Sphera Funds Management fully exited Amicus Therapeutics in Q2 2026, selling an estimated $8.72M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $767M portfolio in Q2 2026.
  • Sphera Funds Management opened 27 new positions and closed 18 in Q2 2026.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $767M.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.